Literature DB >> 8327288

Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs.

G Kronborg1, M B Hansen, M Svenson, A Fomsgaard, N Høiby, K Bendtzen.   

Abstract

The presence of interleukin (IL)-1 receptor antagonist (IRAP) in plasma and sputum from patients with cystic fibrosis (CF) and chronic Pseudomonas aeruginosa lung infection was investigated together with IL-1 alpha, IL-1 beta, IL-6, and tumor necrosis factor-alpha (TNF) in a cross-sectional study. All cytokines were assayed by ELISAs. High concentrations of IRAP, IL-1 alpha, IL-1 beta, IL-6, and TNF in sputum samples and low or nondetectable levels of circulating cytokines were frequently found. Increased concentrations of plasma IRAP are positively correlated with decreasing pulmonary function. In a longitudinal study of serum IRAP, a higher level of IRAP was detected in a group of patients with poor pulmonary function compared to a group with good pulmonary function.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327288     DOI: 10.1002/ppul.1950150506

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  29 in total

Review 1.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

2.  Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis.

Authors:  I M Balfour-Lynn; N J Klein; R Dinwiddie
Journal:  Arch Dis Child       Date:  1997-08       Impact factor: 3.791

3.  Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells.

Authors:  A A Stecenko; G King; K Torii; R M Breyer; R Dworski; T S Blackwell; J W Christman; K L Brigham
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

Review 4.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

5.  Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa.

Authors:  S Jain-Vora; A M LeVine; Z Chroneos; G F Ross; W M Hull; J A Whitsett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 6.  New perspectives in understanding and management of the respiratory disease in cystic fibrosis.

Authors:  S Suter
Journal:  Eur J Pediatr       Date:  1994-03       Impact factor: 3.183

7.  Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa.

Authors:  D Gosselin; J DeSanctis; M Boulé; E Skamene; C Matouk; D Radzioch
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy.

Authors:  Kerstin Pohl; Elaine Hayes; Joanne Keenan; Michael Henry; Paula Meleady; Kevin Molloy; Bakr Jundi; David A Bergin; Cormac McCarthy; Oliver J McElvaney; Michelle M White; Martin Clynes; Emer P Reeves; Noel G McElvaney
Journal:  Blood       Date:  2014-06-16       Impact factor: 22.113

9.  Specific IgG2 antibodies to Pseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis.

Authors:  G Kronborg; T Pressler; A Fomsgaard; C Koch; N Høiby
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

Review 10.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.